about
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine TumoursActivation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis.Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesotheliomaIsothermal multiple displacement amplification: a methodical approach enhancing molecular routine diagnostics of microcarcinomas and small biopsies.ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter TechnologyIdentification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.Interleukin-6 cytokine: a multifunctional glycoprotein for cancer.Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumorsMdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.Cell viability of fibroblasts to pifenidone and sirolimus: a future concept for drug eluting stents.SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString).miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.Research spotlight: sirolimus-coated stents for airway tracheal stenosis: a future 3D model concept with today's knowledge.Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study.FFPE tissue as a feasible source for gene expression analysis--a comparison of three reference genes and one tumor marker.Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.The "COLD-PCR approach" for early and cost-effective detection of tyrosine kinase inhibitor resistance mutations in EGFR-positive non-small cell lung cancer.Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitroSetting out the frame conditions for feasible use of FFPE derived RNAMachine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancerDigital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response
P50
Q27853125-733E6526-A4F4-4769-8C7A-1A13F36539CAQ28246704-7066D631-5AEF-4F9F-A48C-7A1D1BE1B2E0Q33789403-9BF02325-AB34-4AD8-B8A2-A8CF23846CB2Q33914000-355F94A2-F8EE-4ED4-8B0A-BB7F73212C28Q35230721-575A9824-07E7-448E-9FE5-CA9D35AF4F29Q36179285-9379A66A-DEA4-4606-84AB-60952F8587C2Q36413013-217B1620-1C71-4CEB-889F-058A78D69CE6Q36432090-A959674C-129D-4695-8E4B-B1B7C49F0C9FQ37190264-0D256149-8565-4637-9A00-00C7D005980AQ37200413-E3AFE22B-CBCA-48E2-855F-CFDF3705D7D8Q37290519-797E92A3-ADA1-40E6-8BD9-1053ACC1D9CDQ37514029-A1100196-8E63-4AED-96AC-8927298E95DAQ38983373-35109D1E-E5CC-4B27-8D49-A38E831162BBQ39017519-843ADAB5-FEC0-4297-B489-CE2CBABDA054Q39025929-127E0575-4FE1-4A1F-A77F-D956FB0A1522Q40466065-1D8F3E0E-30AD-4425-8B15-03DD04746639Q42412951-17B4BB46-7FAA-49B1-A51F-0F0714D92E81Q43422876-54032B8A-1691-4C61-AF84-A3BF30F90DC2Q44415419-70293606-284F-4BC0-9A3D-80BEEB4CD2E5Q50760839-397BB30A-D5A7-4375-BC23-8DCC2F27B206Q51710878-15B7D676-EBC1-4F1D-9990-6365FC2CBC4DQ53622185-23FFD9BC-50E1-4A32-B568-9591F7686BFDQ55260399-E5EDFDF4-5871-45AE-A924-7EDE762388E1Q55346721-56C18CF0-0EA7-4F5A-9405-590156F4458CQ56976088-1E66A0C4-1DE9-41C9-93C8-C16B1E29A118Q61805843-5DBCE90E-EFFC-4432-A987-FCCE957C7E99Q90869663-2F8CF240-14B3-4F42-8E04-F468D7A7970DQ91500823-D175F9C0-3A6D-46DD-A60B-5F27C85D772EQ91789581-28E71630-0FBE-4C57-8CAB-85A5F90EB8A2
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
R F H Walter
@en
R F H Walter
@nl
type
label
R F H Walter
@en
R F H Walter
@nl
prefLabel
R F H Walter
@en
R F H Walter
@nl
P31
P496
0000-0003-3725-7064